根据最终合并协议,Viewpoint的每一股已发行和流通股份将转换为获得Isoray 3.3212股的权利。Viewpoint股东将拥有Isoray完全稀释的流通股49%的股份。
$华海药业(SH600521)$ $华东医药(SZ000963...查看全文
$Isoray(ISR)$ 内部交易: 2019-11-20,VP of Sales & Marketing,Krachon Michael ,买入,50000普通股, $0.39
$Isoray(ISR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-19-023360 Size: 5 KB 网页链接
$Isoray(ISR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-19-023222 Size: 5 KB 网页链接
$Isoray(ISR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-19-023220 Size: 4 KB 网页链接
$Isoray(ISR)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-19-022946 Act: 33 Size: 591 KB 网页链接
$Isoray(ISR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-19-022693 Act: 34 Size: 2 MB 网页链接
$Isoray(ISR)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001437749-19-022460 Act: 34 Size: 175 KB 网页链接
$Isoray(ISR)$ DEF 14A - Other definitive proxy statements Filed: 2019-10-25 AccNo: 0001437749-19-020660 Size: 1 MB 网页链接
$Isoray(ISR)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-10-25 AccNo: 0001437749-19-020661 Size: 290 KB 网页链接
$Isoray(ISR)$ 8-K - Current report Filed: 2019-10-08 AccNo: 0001437749-19-019804 Size: 19 KBItem 8.01: Other Events 网页链接